Quick Answer
Contineum Therapeutics, Inc. reported Operating Income Loss of -$68.06 million for the year ending 2025.
- Contineum Therapeutics, Inc. showed a decrease of -33.7% in Operating Income Loss from 2024 to 2025.
- This data is from Contineum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2023 to 2025), Contineum Therapeutics, Inc.'s Operating Income Loss has declined by 523.3%.
- Historical annual values: Fiscal year 2025: -$68.06 million | Fiscal year 2024: -$50.89 million | Fiscal year 2023: $16.08 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: